In Brief: Cephalon Myotrophin
Cephalon Myotrophin: Studies in support of a Treatment IND for the amyotrophic lateral sclerosis drug will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on June 7. FDA put the company's treatment protocol on hold due to concerns about data from a European study showing a trend toward higher mortality for Myotrophin compared to placebo. Cephalon plans to file an NDA for Myotrophin later this year. The meeting will be held at the Holiday Inn in Bethesda, Md. starting at 8 a.m...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth